Friday, July 10, 2026

pharma · Schizophrenia · Autosomal Recessive Polycystic Kidney Disease

Otsuka Beijing Research

Otsuka Beijing Research is a pharma organization headquartered in CN. Primary therapeutic focus areas include Schizophrenia, Autosomal Recessive Polycystic Kidney Disease, Multidrug Resistant Tuberculosis, Phenylketonuri

CN HQ
NMPA registrant Type
Company details
Clinical program

Rebamipide

Approved · small molecule · Stomach Ulcer

Rebamipide for Stomach Ulcer is a Approved program (small_molecule) at Otsuka Beijing Research Institute with 1 ClinicalTrials.gov record(s).

Internal code C03700-003

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Otsuka Beijing Research Institute
Phase
Approved
Modality
small_molecule
Indication
Stomach Ulcer
Status
completed
Trials
1

Clinical trials